Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$14.53 +0.3%	$16.55	$3.25 ▼ $21.48	$387.52M	1.18	258,742 shs	243,255 shs
MBX MBX Biosciences	$12.48 +1.2%	$11.43	$4.81 ▼ $27.50	$416.80M	N/A	258,561 shs	92,284 shs
RZLT Rezolute	$4.78 -1.7%	$4.09	$2.22 ▼ $6.19	$412.20M	1.03	647,381 shs	613,041 shs
TNYA Tenaya Therapeutics	$0.61 -0.3%	$0.53	$0.36 ▼ $4.06	$99.54M	3	2.71 million shs	779,192 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	0.00%	+3.68%	-15.80%	+22.78%	+341.49%
MBX MBX Biosciences	0.00%	+16.05%	+5.19%	+106.54%	+1,247,499,900.00%
RZLT Rezolute	0.00%	+9.77%	+10.79%	+88.74%	+14.51%
TNYA Tenaya Therapeutics	0.00%	+0.23%	+13.15%	+22.49%	-79.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	2.7164 of 5 stars	3.5	3.0	2.1	1.7	0.6
MBX MBX Biosciences	3.2529 of 5 stars	3.5	0.0	3.3	3.3	0.6
RZLT Rezolute	2.2604 of 5 stars	3.6	1.0	1.1	4.2	0.0
TNYA Tenaya Therapeutics	3.4553 of 5 stars	3.5	2.0	2.0	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	104.25% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	200.60% Upside
RZLT Rezolute	3.14	Buy	$11.83	147.82% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	922.91% Upside

Current Analyst Ratings Breakdown

Latest TNYA, RZLT, ETON, and MBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/10/2025	MBX MBX Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
4/10/2025	MBX MBX Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00
4/10/2025	MBX MBX Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$38.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$48.33M	8.06	N/A	N/A	$0.94 per share	15.45
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$1.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	29.05	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$1.16	N/A	N/A	N/A	N/A	-92.20%	-74.53%	8/14/2025 (Estimated)

Latest TNYA, RZLT, ETON, and MBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	1.23	1.97	1.43
MBX MBX Biosciences	N/A	N/A	N/A
RZLT Rezolute	N/A	8.43	8.43
TNYA Tenaya Therapeutics	N/A	6.68	6.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
MBX MBX Biosciences	N/A
RZLT Rezolute	82.97%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	16.03%
MBX MBX Biosciences	52.19%
RZLT Rezolute	18.39%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
RZLT Rezolute	40	85.52 million	69.79 million	Optionable
TNYA Tenaya Therapeutics	110	162.67 million	83.53 million	Optionable

TNYA, RZLT, ETON, and MBX Headlines

Recent News About These Companies

Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 0.3% - Here's Why

July 4 at 2:42 AM | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Analysts

June 12, 2025 | marketbeat.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.comA

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.comA

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.comA

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.comA

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

April 24, 2025 | globenewswire.com

Tenaya Slashes a Third of Workforce to Fund Development of Cardio Gene Therapies

April 1, 2025 | biospace.comB

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%

April 1, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, RZLT, ETON, and MBX Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$14.52 +0.05 (+0.31%)

As of 07/3/2025 03:30 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

MBX Biosciences NYSE:MBX

$12.48 +0.15 (+1.18%)

As of 07/3/2025 01:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Rezolute NASDAQ:RZLT

$4.78 -0.09 (-1.75%)

Closing price 07/3/2025 03:04 PM Eastern

Extended Trading

$4.78 0.00 (0.00%)

As of 07/3/2025 04:01 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.61 0.00 (-0.29%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$0.61 0.00 (0.00%)

As of 07/3/2025 04:53 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time